Related references
Note: Only part of the references are listed.Extraskeletal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group
Anna Paioli et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).
Abdul Rafeh Naqash et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
Antoine Italiano et al.
LANCET ONCOLOGY (2020)
Cabozantinib as an emerging treatment for sarcoma
Patrick Schoffski et al.
CURRENT OPINION IN ONCOLOGY (2020)
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
William D. Tap et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2020)
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich et al.
LANCET ONCOLOGY (2020)
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder et al.
LANCET ONCOLOGY (2020)
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
Javier Martin-Broto et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing
Jasmien Cornillie et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky et al.
LANCET ONCOLOGY (2019)
Safety and Tolerability of c-MET Inhibitors in Cancer
Alberto Puccini et al.
DRUG SAFETY (2019)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
Robert J. Motzer et al.
BRITISH JOURNAL OF CANCER (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
Meredith K. Chuk et al.
PEDIATRIC BLOOD & CANCER (2018)
Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas Insights for Personalized Therapy
Carlo Lucchesi et al.
JAMA ONCOLOGY (2018)
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg 51, 2018)
P. G. Casali et al.
ANNALS OF ONCOLOGY (2018)
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
P. Schoffski et al.
ANNALS OF ONCOLOGY (2018)
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon et al.
LANCET ONCOLOGY (2017)
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap et al.
LANCET ONCOLOGY (2017)
Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma
Kenta Mukaihara et al.
PLOS ONE (2017)
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'
P. Schoffski et al.
ANNALS OF ONCOLOGY (2017)
Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma
Elliot Kahen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Matthew Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schoffski et al.
LANCET (2016)
Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study
Antoine Italiano et al.
LANCET ONCOLOGY (2016)
Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study
Martee L. Hensley et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
Katja Schmitz et al.
PLOS ONE (2015)
Activity of sunitinib in extraskeletal myxoid chondrosarcoma
S. Stacchiotti et al.
EUROPEAN JOURNAL OF CANCER (2014)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson et al.
LANCET ONCOLOGY (2014)
Cediranib for Metastatic Alveolar Soft Part Sarcoma
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen
C. F. Verschraegen et al.
ANNALS OF ONCOLOGY (2012)
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
Farbod Shojaei et al.
CANCER LETTERS (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
Barbara Sennino et al.
CANCER DISCOVERY (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma
Ian J. Davis et al.
CANCER RESEARCH (2010)
Gene expression profiling of alveolar soft-part sarcoma (ASPS)
Luke H. Stockwin et al.
BMC CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma
Chong-Feng Gao et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Extraskeletal Myxoid Chondrosarcoma A Retrospective Review From 2 Referral Centers Emphasizing Long-term Outcomes With Surgery and Chemotherapy
Alex D. Drilon et al.
CANCER (2008)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity
Chongmin Huan et al.
NATURE IMMUNOLOGY (2006)
c-Met ectodomain shedding rate correlates with malignant potential
Gagani Athauda et al.
CLINICAL CANCER RESEARCH (2006)
Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma
A Potti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Scatter-factor and semaphorin receptors: Cell signalling for invasive growth
L Trusolino et al.
NATURE REVIEWS CANCER (2002)
Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors
V Wallenius et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
